Scientific deep-dive
Semaglutide and Motivation
Semaglutide reduced how heavily people with depression discounted effort, while leaving their sensitivity to probability unchanged. That dissociation is what makes the finding hard to dismiss.
In a randomized trial, semaglutide reduced how heavily people with major depressive disorder discounted effort, making them more willing to work for a reward.[1] The same trial missed its primary cognitive endpoint, which is a reason for caution. What makes this particular secondary finding more interesting than most is what it did not move.
What was measured
Effort-based decision-making tasks ask people to choose between an easy task for a small reward and a harder one for a larger reward. Computational modeling then separates two things that look similar from the outside: how much someone dislikes effort, and how much they discount an uncertain payoff.
| Parameter | Effect of semaglutide | p |
|---|---|---|
| Sensitivity to effort | β = −1.737 (reduced) | 0.03 |
| Sensitivity to probability | β = −0.776 | 0.51 |
The authors describe the result as a reduction in the perceived cost of effort relative to the monetary reward.[1] Things felt less expensive to do.
Why the null in the second row matters
A general lift in mood, engagement or expectation should move both parameters. This moved one.
That dissociation is the strongest thing about the finding. If participants had simply felt better, or tried harder because they believed they were on an active drug, you would expect their whole approach to the task to shift. Instead one specific parameter moved and a closely related one did not.
It is not proof of a mechanism, but it is the kind of specificity that separates a plausible signal from the general warm glow that contaminates most secondary psychiatric outcomes.
The caution that has to travel with it
This is a secondary analysis of a trial whose primary endpoint failed. Executive function, the outcome the study was built and powered to test, showed no effect, with a confidence interval spanning zero. When a primary fails and secondaries succeed, the trial has answered its question with a no, and the secondaries are suggestions for the next study.
The parent trial also found no effect on depressive symptom severity. Mood did not change, so whatever this is, it is not an antidepressant effect showing up on a motivation measure.
Why it is being taken seriously anyway
The authors note implications for neuropsychiatric disorders characterized by reward dysfunction, a group that includes depression, schizophrenia and substance use disorders. This connects to a body of work we have covered: a randomized trial in alcohol use disorder that found a real effect, cohort data showing lower rates of worsening substance use, and health records in which people with opioid use disorder who had a GLP-1 prescription overdosed less often.
A drug that changes how costly effort feels, and that separately cut drinks per drinking day and craving in a 48-person randomized trial,[2] is doing something to reward processing. What that something is, and whether it helps anyone in a way they would notice, is not settled by a task in a laboratory.
Frequently Asked Questions
References
- 1.Gill H, Badulescu S, Shah H, et al. Semaglutide and Effort-Based Decision-Making in Major Depressive Disorder: A Randomized Clinical Trial JAMA Psychiatry. 2026. PMID: 42054055.
- 2.Hendershot CS, Bremmer MP, Paladino MB, et al. Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial JAMA Psychiatry. 2025. PMID: 39937469.
Compare the sellers
Related research
When the Primary Endpoint Fails and a Secondary Doesn't
A randomized trial in 72 people with major depressive disorder found no effect on executive function, its primary outcome. A secondary cognition measure cleared p=0.03, and that is the one that will be reported.
5 min read
Semaglutide and Alzheimer's: The Trials Came Back Negative
Two randomized trials in 3,808 people with early Alzheimer's found no difference in cognitive decline at two years. Both were discontinued for negative clinical outcome. The 45% figure came from studies measuring something else.
6 min read
GLP-1s and Epilepsy Risk
People on GLP-1 drugs developed epilepsy less often than those on a different diabetes drug (hazard ratio 0.84). But the association was strongest at one year and weaker at five, which is backwards for neuroprotection.
5 min read
GLP-1s and Worsening Mental Illness
Semaglutide was associated with 42% lower risk of worsening mental illness in people with depression and anxiety. Exenatide and dulaglutide showed nothing. Four drugs, one class, two very different results.
5 min read
Tirzepatide Versus Semaglutide on Mood
Across more than 85,000 matched pairs over two years, psychiatric outcomes were the same for both drugs. Against older GLP-1s, semaglutide was associated with about half the hazard of suicidal ideation.
5 min read
GLP-1s and Antipsychotic Weight Gain: A Trial Cut Short
Semaglutide produced 13.88% weight loss against 0.42% on placebo in people taking clozapine, without altering clozapine levels or psychotic symptoms. The trial ended at 31 of an intended 80 because the drug ran out.
6 min read
Where to get semaglutide online, safely: sellers our editors have checked
These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.
No insurance needed · vetted by our editors
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
YourEra
From $99/mo
Get started →Eden
Coverage in all 50 states, which most sellers will not confirm
From $99/mo
Get started →Found
People who want clinician visits billed to commercial insurance, with compounded medication in the plan price
From $289/mo
Get started →